Hygieia touts certified fisetin production for nutraceutical buyers

Shenzhen Hygieia Biotech is pitching FSSC 22000 and FDA-registered manufacturing as a quality signal for fisetin and other senolytic ingredients used in cellular health supplements. The company says the certifications and biosynthetic production methods help reduce contamination risk, improve consistency, and support global formulation work.

Why it matters: - Nutraceutical brand managers and procurement teams are under more pressure to verify ingredient quality, purity, and safety. - Fisetin sourcing can affect finished-product consistency, traceability, and regulatory readiness. - Certified manufacturing is positioned as a way to lower risk in cellular health supplement supply chains.

What happened: - Shenzhen Hygieia Biotech Co., Ltd. promoted its fisetin manufacturing standards on October 23, 2026, in Shenzhen, Guangdong, China. - The company highlighted FSSC 22000 certification and FDA-registered production as core quality controls for premium senolytic ingredients. - Hygieia also pointed to its role as a manufacturer of cellular health raw materials for global nutraceutical customers.

The details: - Hygieia says certified fisetin production offers full traceability, structural consistency, and active ingredient stability. - The company contrasted certified fisetin with uncertified supply, citing risks such as variable botanical origin, incomplete solvent removal, and purity fluctuations. - Hygieia said verified production uses High-Performance Liquid Chromatography testing to confirm identity and potency before shipment. - FSSC 22000 combines ISO 22000 requirements with sector-specific prerequisite programs and a full food safety risk framework. - Hygieia said FDA registration adds continuous compliance controls for environmental conditions, cross-contamination prevention, and batch genealogy. - The company said its manufacturing lines are aligned with international safety benchmarks for bulk active ingredients used in multi-ingredient formulations. - Hygieia described itself as a high-tech enterprise focused on synthetic biology, research and development, and industrial production of anti-aging ingredients. - The company said its proprietary Zymevolver strain construction technology and enzyme engineering platform support design of precise molecular compounds. - Hygieia said it produces Ca-AKG, NMN, PQQ, DCI, and L-5-MTHF through enzymatic and fermentation pathways. - The company said biosynthetic production can improve purity, reduce pesticide residue risk, limit batch variation, and lower environmental impact compared with traditional extraction. - Hygieia said it maintains internal safety evaluation and efficacy validation systems. - The company said those systems support custom formula development, raw material optimization, and OEM/ODM manufacturing for nutrition, personal care, and biomedical partners. - Hygieia’s corporate portal is available at more information.

Between the lines: - The release is aimed at buyers who view certification as a proxy for supply-chain reliability. - Hygieia is framing biosynthesis as both a quality upgrade and a sustainability improvement versus agricultural extraction. - The message also positions certification as a commercial differentiator in a crowded supplement ingredient market.

What's next: - Hygieia is directing buyers to its website for technical documentation, quality certifications, and its broader portfolio of cellular health raw materials. - The company is likely to continue using certification and biosynthetic manufacturing as sales points for global sourcing teams. - Buyers interested in custom formulations can pursue raw material development, dosage-form optimization, and finished-product OEM/ODM support through Hygieia.